ChemDiv

ChemDiv is a full-service target-to-clinic contract research organization (CRO) providing a broad range of services to accelerate the discovery and development of new drugs. The company has more than 30 years of industrial experience and has successfully completed hundreds of leads, candidates and new drug programs for a variety of diseases, including cancer, neurological, infectious, cardiometabolic and immune disorders.

At the heart of ChemDiv's approach is the strategic application of Hybrid Artificial Intelligence (AI) and Machine Learning (ML) curated by scientists at every stage of the process. This helps to streamline and accelerate the discovery of new drugs and treatments.

Their catalog includes a broad range of screening libraries, including:

• Focused and Targeted Libraries: 114 predesigned libraries organized by therapeutic areas, targets and mechanism of action.
• Active Reference Sets: 17 annotated libraries with over 220,000 compounds, 25,000 targets and 1,000,000 activity data points across many areas.
• Diversity Libraries: Representative diversity sets covering the space of billions of compounds, both 2D and 3D.
• Preplated Libraries: A collection of 30 billion virtual drug-like and lead-like compounds, optimized for solubility and target diversity.
• Inhibitors and Approved Drugs: Small molecule inhibitors and approved drugs for repurposing.
• Building Blocks: Compounds available for search and purchase.
• Substructure Search for Screening Compounds: Search and purchase from the largest commercially available space with regular new additions.
• Inhibitors: Search and purchase inhibitors from an extensive collection.
• Download Database: Access to over 1.6 million screening compounds, 70,000 building blocks and 45,000 inhibitors and drugs.

ChemDiv also provides a range of integrated services to support the entire drug discovery process, including:

• Target ID: Lead discovery, lead optimization, IND and FIM studies.
• IP Strategies and Support: Expertise in IP protection and management.
• Synthetic and Medicinal Chemistry: Design and synthesis of novel compounds.
• Hybrid AI/ML Rational Design: AI-driven design of new compounds.
• Discovery Biology: Functional and ex vivo models for target validation.
• ADME, DMPK: In vitro and in vivo studies for compound optimization.
• Safety and Toxicology: GLP and CMP CMC support for regulatory submissions.
• Regulatory and Clinical Trials: Expert guidance for clinical trial preparation and execution.

ChemDiv's comprehensive collection of compounds and integrated services help researchers and organizations accelerate their drug discovery and development projects, combining the strengths of human expertise and AI-driven tools to drive innovation.

Published on August 10, 2024